the fy21 defense appropriations act provides funding to the department of defense bone marrow failure research program (bmfrp) to support research of exceptional merit that focus on bone marrow failure diseases. the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 bmfrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.

the objective of the fy21 bmfrp is to fund scientifically meritorious research focused on bmf diseases. investigator‐initiated research is encouraged in the areas of congenital or acquired bmf. studies focused on bmf syndromes and their progression to other malignancies, such as leukemia, are acceptable. however, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. stem cell biology studies and translational projects, including bone marrow transplantation studies, should be clearly related to bmf diseases.

https://cdmrp.army.mil/funding/bmfrp

idea development award – preproposal due july 9, 2021

• established investigator: independent investigators at or above the level of associate professor (or equivalent) or an assistant professor (or equivalent) with 10 years or more from his/her first faculty appointment (or equivalent) by the application submission deadline.
• early career investigators: independent investigators at the level of assistant professor (or equivalent), and within 10 years from his/her first faculty appointment (or equivalent) by the application submission deadline.
• supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (bmf) diseases.
• proposed research should have a high probability of revealing new avenues of investigation.
• research project should include a well–formulated, testable hypothesis and a well-developed and articulated research approach.
• must address at least one of the fy21 bmfrp ida focus areas.
• strong bmf research team.
• may include relevant preliminary data.
• clinical trials are not allowed.
• translational potential should be considered and described.
• pre-application is required; application is by invitation only.
  • the maximum period of performance is 3 years.
• the maximum allowable funding for the entire period of performance is $450,000 in direct costs (plus indirect costs).

investigator-initiated research award (iira) – preproposal due july 9, 2021

investigators at or above the level of assistant professor (or equivalent) by the application submission deadline.

• two funding levels of intent:

Ø  funding level 1: supports studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in bmf research, patient care, and/or quality of life. correlative studies to existing clinical trials/studies are encouraged.

translational potential should be considered and described.

• funding level 2: investigational new drug (ind)-enabling efforts the proposed studies should be empirical in nature, product driven, and focused on the accumulation of data to support an ind application to the u.s. food and drug administration.  applicants are required to identify lead bmf therapy candidate(s), and transition plans should be considered and adequately described.
• emphasis on research approach and impact.
• strong bmf research team.
• preliminary data required.
• clinical trials are not allowed.
• must address at least one of the fy21 bmfrp iira focus areas.
• partnering pi option: allows two pis, termed initiating and partnering pis, to collaborate on a single application.

pre-application is required; application is by invitation only

funding level 1:

• the maximum period of performance is 3 years.
• maximum funding of $600,000 in direct costs (plus indirect costs).

funding level 2: ind-enabling efforts

• the maximum period of performance is 4 years.
• maximum funding of $800,000 in direct costs (plus indirect costs).

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the bmfrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

he fy21 defense appropriations act provides funding to the department of defense lupus research program (lrp) to support the full spectrum of research projects or ideas that specifically focus on scientific and clinical lupus issues, which, if successfully addressed, have the potential to make a major impact in lupus research.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate manages the defense health program (dhp) research, development, test, and evaluation (rdt&e) appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the congressionally directed medical research programs (cdmrp) at the u.s. army medical research and development command (usamrdc).

the fy21 lrp program announcements and general application instructions for the following award mechanisms are posted on the grants.gov website.    

applications submitted to the fy21 lrp must address one or more of the following focus areas:

• understanding how lupus disease heterogeneity impacts risk of disease, disease presentation, clinical course, and outcomes; using a diverse range of research disciplines including, but not limited to, biopsychosocial studies, personalized medicine, variation in treatment studies, health economics, socioeconomic studies, environmental studies, and epidemiological studies.
• understanding mechanisms of lupus disease, using mechanistic studies, strategies, and technologies including, but not limited to, informative, rare patients.
• determining the pathobiology of end organ injury lupus disease in target human tissues.
• improving quality of life for individuals living with lupus including, but not limited to, addressing social determinants of health, access to healthcare resources, outcomes research, patient-reported outcomes, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling.
• understanding the underlying genetic and epigenetic components and gene-environment interactions of lupus and how they may relate to clinical disease characteristics, variations, and differences in response to therapies using functional genomic studies.

applications submitted to the fy21 lrp transformative vision award must address the following focus area:

• design and implement an intervention including, at the individual and/or healthcare system level, improving quality of life for, but not limited to, access to healthcare resources, outcomes research, symptom and disease control, comparative effectiveness research, and issues and challenges that, when addressed, make day-to-day living with lupus easier and life more fulfilling.

https://cdmrp.army.mil/funding/lrp

idea award – letter of intent due august 24, 2021

investigators at or above the level of postdoctoral fellow (or equivalent)

• supports innovative, high-risk/high-reward research that could ultimately lead to a critical discovery or major advancement relevant to lupus.
• must address one of the fiscal year 2021 (fy21) lrp focus areas.
• emphasis is on innovation
• clinical trials are not allowed
• preliminary data are not required.
• the maximum allowable funding for the entire period of performance is $300,000 for total costs (direct plus indirect costs)
• the maximum period of performance is 2 years

impact award – letter of intent due august 24, 2021

independent investigators at or above assistant professor (or equivalent)

• supports high-risk/high-reward research which, if successfully addressed, has the potential to make a major impact in lupus research
• emphasis is on impact
• must address one of the fy21 lrp focus areas
• clinical trials are not allowed
• preliminary data are encouraged but not required
• the maximum allowable funding for the entire period of performance is $750,000 for total costs (direct plus indirect costs)
• the maximum period of performance is 4 years

transformative vision award – letter of intent due august 24, 2021

independent investigators at or above assistant professor (or equivalent)

• supports research that will have an intervention at the individual and/or healthcare system level, which will result in near-term impact on the health-related quality of life of persons living with lupus
• emphasis is on near-term impact to quality of life
• must address the fy21 lrp tva focus area
• human subject research and clinical trials are allowed.
• preliminary data are required
• animal studies are not allowed.
• partnering principal investigators  (pi) option allows one initiating investigator and a maximum of two partnering pis 
• new – the research team must include one of more consumer advocate(s).
• the maximum allowable funding for the entire period of performance is $2.5 million for total costs (direct plus indirect costs)
• the maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final program announcements and general application instructions that will be available for electronic downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when program announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the lrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

the specific objective of this funding opportunity is:

• to improve the efficacy of personalized treatment of cancer patients through the development of new tools and targeted immunotherapy strategies, based on a better understanding of tme functions and of their impact on the disease course.

to accelerate translational cancer research so that precise, impactful and cost-effective treatments can benefit cancer patients, oicr has implemented a new clinical translation pathway (ctp). the ctp will support practice-changing research in biomarkers, diagnostics and therapeutics that will advance early detection and intervention research and have a clear path to the clinic and clinical impact. it will focus on primary-diagnosed or early recurrent cancers. the pathway will be fueled by innovations emerging from oicr-supported research and from research originating from across the province of ontario.

the ctp consists of separate funding streams that support preclinical, clinical, and convergent research. oicr is currently inviting applications for the following two funding streams:

pre-clinical acceleration team awards (pre-cata): supports pre-clinical projects with a clear path to the clinic, with a focus on pre-clinical development of biomarkers, diagnostics and therapeutics.

funding available: $250,000 per year for up to three years. oicr anticipates supporting up to eight pre-cata projects.

clinical acceleration team awards (cata): supports early phase (i-ii), prospective, biomarker-rich trials for clinical validation of biomarkers, diagnostics and therapeutics.

funding available: $500,000 per year for up to three years. oicr anticipates supporting up to eight cata trials.

the call is open! mitacs globalink research internship (gri) is now accepting faculty project submissions for summer 2022. gri pairs faculty in canada with international undergrads for 12-week research projects from may to october.

the globalink program builds international networks and experiences, and positions canada as a top destination for innovation and research among 世界杯2022赛程表淘汰赛 from abroad.
 

• all disciplines are eligible
• top-ranked senior undergrads travel from australia, brazil, china, colombia, france, germany, hong kong, india, mexico, taiwan, tunisia, ukraine, united kingdom, and united states.
• faculty can submit multiple projects and re-submit projects from previous years

submit projects by june 9, 2021 at 1 p.m. pt.

please contact jill sherman, international research facilitator, for more information at intl.research@lakeheadu.ca

the trans-atlantic platform (t-ap) for social sciences and humanities launches its third joint research call for proposals. the recovery, renewal and resilience in a post-pandemic world (t-ap rrr) call brings together 16 humanities and social science research funding agencies, including the social sciences and humanities research council (sshrc), from 12 countries in south america, north america and europe. t-ap rrr will support international projects that contribute to our understanding of the complex societal effects of the covid-19 pandemic. the são paulo research foundation in brazil is the lead organization for the call.

t-ap rrr is open to teams with members from at least three participating countries, representing both sides of the atlantic. research partners will receive funding from the national funding agency for their country, for projects that can last up to 36 months. applicants are required to submit novel interdisciplinary and significant social sciences and humanities research proposals that address one or more of five identified challenges:

• reducing inequalities and vulnerabilities
• building a more resilient, inclusive and sustainable society
• fostering democratic governance and political participation
• advancing responsible and inclusive digital innovation
• ensuring effective and accurate communication and media

please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca if you are interested in this funding opportunity.

the specific objective(s) of this funding opportunity are:

• to address all of the objectives of this funding opportunity within an indigenous health research context. that is, the approach to the funding opportunity objectives will need to be conducted by, grounded in, or engaged with first nations, inuit or métis communities, societies or individuals and their wisdom, cultures, experiences or knowledge systems, as expressed in their dynamic forms, past and present.
• to build on the infrastructure, capacity and partnerships developed by the three previously cihr-funded i-helti team grants in order to conduct one i-helti intervention cohort research study and to establish one i-helti collaborating centre, including the following four activities: (1) recruiting women, both preconception and during pregnancy, their infants and the fathers; (2) designing an intervention to develop, conduct and evaluate interventions for and with women and men during preconception, pregnancy and, for infants, during the postnatal period to substantially reduce the prevalence of ncds; (3) conducting evaluative and mechanistic studies that will explain the effect of the selected interventions on outcomes, including epigenetic and economic analyses of interventions; and (4) developing governance processes, including research data management practices.
• to develop cross-community collaborations that will provide an interdisciplinary learning platform and training environment for early career researchers and trainees.
• to generate evidence that will guide policy and other decision making, and identify opportunities for future research and interventions as part of a longer-term strategy of ncd prevention.
• to decrease the incidence of risk factors for later-life ncds by targeting early exposures and early development, particularly related to women’s and men’s health preconception, during pregnancy, early life and in early childhood.
• to establish a platform for sustained investments through long-term indigenous community engagement and institutional commitments.

the national contaminants advisory group (ncag) of fisheries and oceans canada (dfo) provides information and scientific advice to dfo and other departments on priority issues related to biological effects of contaminants on aquatic organisms. one of the functions of this group is to provide funding for external researchers who study these priority areas related to contaminants.

we are happy to announce that dfo has started a new round of funding for research supporting our ministerial priorities, including priorities related to the biological effects of contaminants.

for this round of funding, the priorities for ncag are as follows:

1)    knowledge about the impact of 6ppd-quinone and other transformation products on canadian salmonid populations and the determination of mechanisms of action is required. in addition, further information on how toxic 6ppd transformation products are to other aquatic species would be beneficial.

2)    current-use pesticides may be applied in mixtures of several active ingredients as well as adjuvants, and once these compounds reach the environment, they may combine with numerous other contaminants (particularly pahs, flame retardants, caffeine, detergents but also excessive nutrients, metals, pharmaceuticals and personal care products). proposals are invited on the effects of these mixtures, and the role of pesticides and/or adjuvants within them, on non-target aquatic biota.

3)    further knowledge on the biological effects of disinfectants on aquatic organisms near wastewater effluent is needed to determine the risks for aquatic ecosystems. some examples of current-use antimicrobials include triclosan, triclocarban, chlorophene, quaternary ammonium compounds, benzalkonium chloride, etc.

if you are interested, we invite you to submit an application for funding. the guidelines for the submission of a research proposal, a budget template and an example budget table are available at the following address: ecosystems and oceans science contribution framework (dfo-mpo.gc.ca).

the deadline for submitting a project is 11:59 pm eastern standard time (est) on may 20, 2021.

please send all questions to the email address: opc-bpc@dfo-mpo.gc.ca.

the workplace safety and insurance board (wsib) is now accepting proposals for the 2021 grants program strategic initiative: occupational asbestos exposure and development of gastro-intestinal cancers (systematic review)

proposal deadline: monday, may 31, 2021

to express interest and obtain an application form, please email grants@wsib.on.ca.

new funding opportunity

the wsib is seeking applications for a new funding competition. the wsib grants program will be awarding one successful application for a systematic review of the scientific evidence examining if occupational asbestos exposure causes gastro-intestinal cancers.

outcomes from the systematic review may be considered by the wsib to determine whether the scientific evidence meets the recommended standards for scheduling, policy development or to underpin adjudicative support in case-by-case decision-making.

the review must address:

• gastro-intestinal cancers and the individual cancers (i.e. cancers of the esophagus, stomach, small bowel, colon and rectum)
• individual types of asbestos (i.e. chrysotile, crocidolite, amosite, tremolite, actinolite and anthophyllite) where possible
• identification of

o   any dose-response relationships

o   interdependent causes or synergistic relationships

o   subgroups of workers who have an increased risk of developing gastrointentinal cancers and/or any of the individual cancers

• examine any evidence for a minimum interval (latency) between the first exposure to asbestos and the diagnosis of gastrointestinal cancer and/or any of the individual cancers

for more information about the strategic initiative and the application process, please visit our website.to express interest and obtain an application form, please email grants@wsib.on.ca.

sincerely,